《大行報告》瑞信上調君實生物(01877.HK)目標價至65元 評級「跑贏大市」
瑞信發表評級報告指,君實生物(01877.HK)除了特瑞普利單抗注射液(PD-1)銷售表現低於預期,其去年業績表現符合早前初步數據;該行預料美國或會延遲批准PD-1,以及管理層目標今年國內PD-1銷量翻倍。
該行指,基於收入預測下調及營運成本增加,該行下調集團2022年及23年每股盈測235%及895%。由於近期在中國市場推出PD-1仍存有不確定因素,將公司每年2022年至23年總收入下調52%及44%,惟受惠於早前已完善的生產線,料未來數年公司長期收入增長會增加,目標價由60元上調65元,維持其評級「跑贏大市」。(ca/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.